Risk.net

Progress on US banks’ EVE transparency grinds to a halt

No additional disclosures of key metric linked to SVB collapse in latest round of public filings

  • LinkedIn  
  • Save this article
  • Print this page  

Nearly 18 months after the collapse of Silicon Valley Bank, progress to improve US banks’ transparency on their economic value of equity (EVE) sensitivity – an indicator that assesses the impact of interest rate changes on the net cashflow of a bank’s balance sheet – have stalled.

A Risk Quantum analysis found the number of banks disclosing figures for EVE sensitivity remained unchanged between December 2023 and June 2024.

!function(e,n,i,s){var d="InfogramEmbeds";var o=e.getElementsByTagName(n)

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Copyright Infopro Digital Limited. All rights reserved.

As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.

If you would like to purchase additional rights please email info@risk.net

Copyright Infopro Digital Limited. All rights reserved.

You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.

If you would like to purchase additional rights please email info@risk.net

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

More on Risk Quantum

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here